ESH ALL 2021 | Development of novel menin-MLL inhibitors for acute leukemias
Scott Armstrong, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the development of novel menin-MLL inhibitors, particularly SNDX-5613. Menin-MLL inhibitors disrupt the interaction between menin and the MLL1 fusion proteins required for leukemogenic activity. These inhibitors are currently being evaluated in clinical trials for the treatment of adult and pediatric patients with relapsed or refractory MLL-rearranged acute leukemias. Early clinical data reveals impressive responses with minimal toxicities. Although these are still preliminary results, this approach may be clinically valuable. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.
Disclosures
Sponsored Research: Syndax Pharmaceuticals, Novartis, Janssen.
Scientific Advisory Board: C4 Therapeutics, Imago Biosciences, Neomorph Inc.
